Reports Q4 revenue $4.96M, consensus $4.32M."Our fourth quarter results demonstrated significant progress on our strategic and financial objectives, as we achieved our highest level of quarterly sales on record while also registering our lowest level of cash burn and operating expenses since IPO," said David Roman, President & CEO of Acutus. "As we enter 2023, our focus turns from stabilization to growth through increased adoption of our differentiated mapping and therapy platform, and geographic expansion as well as continued improvement in our financial profile."
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on AFIB:
- Acutus Medical Reports Fourth Quarter and Full Year 2022 Financial Results
- Acutus Medical management to meet virtually with BTIG
- Acutus Medical to Announce Fourth Quarter and Full Year 2022 Financial Results
- Acutus Medical Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Late-Breaking ACQFORCE FLUTTER Trial Meets Primary Endpoint for Safety and Efficacy with the First Gold-Tipped Contact Force Sensing Ablation Catheter
